Omeprazole Market - Regional Analysis
North American Market Insights
North America industry is set to dominate majority revenue share of 59% by 2035. In 2020 the region experienced the prevalence of H. pylori infection which causes ulcers. Additionally, peptic ulcers are prominent in the US, around 4.5 million individuals are affected yearly. Also, about 10% of the US population is affected by duodenal ulcers. For example, there is an online service that helps people save around 80% on their prescription costs by working with large pharmacies in the US. These key factors are bolstering the market growth of Omeprazole in the region.
APAC Market Insights
Asia Pacific to hold a share of 28.6% by 2035. Market growth in the region is driven by greater awareness amongst target audiences about treating this condition, growing incidences, and intensified focus of key market players to increase their product portfolio. Vonoprazan, a product that is FDA-cleared for the treatment of gastroesophageal reflux disease by Phantom Pharmaceutics, was made available to Japanese consumers and another Asian country in March 2022. In addition, with the increased demand for gastroesophageal disease treatment in the Asia region, a number of players have been expanding their presence there.
